Blueprint Genetics

About:

Blueprint Genetics is a healthcare firm based in Helsinki, San Francisco and Dubai, providing clinical genetic testing to patients.

Website: http://www.blueprintgenetics.com

Twitter/X: BpGenetics

Top Investors: Stanford University, Inventure, Cota Capital, MTIP AG, Creathor Ventures

Description:

Blueprint Genetics provides genetic diagnostics of rare diseases based on Next-Generation Sequencing (NGS). The professional genetic tests are targeted for hospitals and research groups. Blueprint Genetics aims to disrupt the market by decreasing the price level of genetic diagnostics significantly while increasing quality and adding clinical insight to the results statements. The tests are based on a novel NGS method called OS-Seq:tm: that was developed in the Stanford University. The product roadmap of the company covers a long list of diagnostics for different hereditary diseases. The currently available products cover relevant rare hereditary cardiovascular diseases, such as cardiomyopathies, arrhythmias and aorta diseases. The company is based in Helsinki, Finland and has an office also in Los Angeles, CA.

Total Funding Amount:

$26.3M

Estimated Revenue Range:

$10M to $50M

Headquarters Location:

Helsinki, Southern Finland, Finland

Founded Date:

2012-04-01

Contact Email:

support(AT)blueprintgenetics.com

Founders:

Juha Koskenvuo, Samuel Myllykangas, Tero-Pekka Alastalo, Tommi Lehtonen

Number of Employees:

11-50

Last Funding Date:

2020-09-07

IPO Status:

Private

Industries:

© 2025 bioDAO.ai